Baker Hughes is a leading supplier of oilfield services and technology. The document discusses Baker Hughes' operations in Norway, including its revenue, employees, facilities, and supply chain logistics. It notes that Baker Hughes is testing the use of sea transport between its Stavanger and northern Norway locations to reduce the number of trucks needed and improve sustainability, as the activity in the northern regions is increasing. Key considerations for using sea transport include reliability, flexibility, price, and environmental impact.
Samskip is a globally active transportation company offering services by land, sea, rail, and air. It has over 1,200 employees and operates out of 55 offices in 23 countries. Samskip provides multimodal transportation solutions utilizing short sea shipping, rail, road, and barge to reliably and sustainably transport goods across its network in Europe, North and South America, and Asia. Key services include temperature controlled transport, international forwarding, and storage.
Baker Hughes is a leading supplier of oilfield services and technology. The document discusses Baker Hughes' operations in Norway, including its revenue, employees, facilities, and supply chain logistics. It notes that Baker Hughes is testing the use of sea transport between its Stavanger and northern Norway locations to reduce the number of trucks needed and improve sustainability, as the activity in the northern regions is increasing. Key considerations for using sea transport include reliability, flexibility, price, and environmental impact.
Samskip is a globally active transportation company offering services by land, sea, rail, and air. It has over 1,200 employees and operates out of 55 offices in 23 countries. Samskip provides multimodal transportation solutions utilizing short sea shipping, rail, road, and barge to reliably and sustainably transport goods across its network in Europe, North and South America, and Asia. Key services include temperature controlled transport, international forwarding, and storage.
Health and fitness apps and devices collect users' personal data, but it is unclear how user data is monetized and who earns from it. A proposed solution is a personal health record platform with an open app store that crowd-sources app development and takes a percentage of app store revenues, while providing platform-level privacy and easy data access. This could form the basis of a new business model for personal health and healthcare data.
This document discusses using ELISA without washing steps by developing a switchable reporter enzyme system. It describes tuning a beta-lactamase enzyme and its inhibitor protein to have high affinity binding and then using this system for wash-free ELISA assays. The goal is to create assays that are faster and require less hands-on time by eliminating washing steps traditionally required in ELISA.
Jack Schalken has co-founded two companies - NovioGendix in 2006 and Oncodrone in 2013 - to translate his translational research into clinical applications and products. As an "entrepreneurial scientist", he learned important lessons about negotiating terms with his academic institution, building a management team, securing financing, and acquiring business skills to successfully launch and grow these ventures. Both companies have worked to bridge the gap between research and clinical validation or product development for cancer diagnostics and therapeutics.
Health and fitness apps and devices collect users' personal data, but it is unclear how user data is monetized and who earns from it. A proposed solution is a personal health record platform with an open app store that crowd-sources app development and takes a percentage of app store revenues, while providing platform-level privacy and easy data access. This could form the basis of a new business model for personal health and healthcare data.
This document discusses using ELISA without washing steps by developing a switchable reporter enzyme system. It describes tuning a beta-lactamase enzyme and its inhibitor protein to have high affinity binding and then using this system for wash-free ELISA assays. The goal is to create assays that are faster and require less hands-on time by eliminating washing steps traditionally required in ELISA.
Jack Schalken has co-founded two companies - NovioGendix in 2006 and Oncodrone in 2013 - to translate his translational research into clinical applications and products. As an "entrepreneurial scientist", he learned important lessons about negotiating terms with his academic institution, building a management team, securing financing, and acquiring business skills to successfully launch and grow these ventures. Both companies have worked to bridge the gap between research and clinical validation or product development for cancer diagnostics and therapeutics.